A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Phase 2 Completed 182 enrolled Bristol-Myers Squibb

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

Timeline

Start: 2017-02-02
Primary completion: 2021-11-23
Completion: 2021-11-23

Publications

Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH Jr, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. J Immunother Cancer. 2022 Nov;10(11):e005780. doi: 10.1136/jitc-2022-005780.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-813160	Small molecule	—	—
Comparator	Ipilimumab	Monoclonal antibody	1 mg/kg	—
Subject	LINRODOSTAT	Small molecule	—	—
Subject	Relatlimab	Monoclonal antibody	—	—
Background	Nivolumab	Monoclonal antibody	480 mg	—

Indications

No indication recorded.